Maarten van der Doelen

Impact of DNA damage repair defects on response to radium-223 therapy in mCRPC patients

Supplementary table 4B. Multivariate analysis of overall survival.

Hazard ratio

95% CI

N

P

Mutation in DDR genes

93

DDR-

65

1.00

DDR+ 0.036 Variables with a P value < 0.20 in univariate analysis were included for multivariable Cox regression analysis. The multivariable Cox regression model was fitted by including variables in the model with a forward selection strategy based on Wald’s test at a significance level of 0.05 at every step. Variables not included in the multivariable Cox regression model: - Baseline alkaline phosphatase level; P 0.077 - Opioid use; P 0.350 - PARP or platinum after radium-223; P 0.616 Supplementary table 5. Outcomes of patients with pathogenic homologous recombination deficiency (HRD) alterations. Group HRD - N = 67 Group HRD + N = 26 Hazard ratio 95% CI P 28 0.49 0.24-0.95

0.012

Median overall survival, months

18.23

36.37

2.326 1.206-4.487

Time to ALP progression, months

5.75

7.03

1.650 0.957-2.844 0.072

Time to next systemic therapy, months

7.29

9.00

1.682 0.989-2.861 0.055

Time to first SRE, months 1.157 0.588-2.279 0.672 ALP, alkaline phosphatase; CI, confidence interval; HRD, homologous recombination deficiency; SRE, skeletal related event. 20.70 23.59

7

195